Search

Search Constraints

You searched for: Author/Creator Pegu, Amarendra

Search Results

1. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. Issue 1 (1st January 2021)

2. Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency. Issue 1 (31st December 2023)

3. Eliminating antibody polyreactivity through addition of N‐linked glycosylation. (12th May 2015)

4. Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Issue 9 (2nd September 2018)

5. Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. Issue 1 (1st January 2020)

6. Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. Issue 1 (1st January 2020)

7. Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. Issue 1 (1st January 2020)

8. Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. Issue 1 (1st January 2020)